Back to results
US 11,299,786 B2Granted
Gene panel to predict response to androgen deprivation in prostate cancer
AssigneeRutgers, The State University of New Jersey
InventorsAntonina Mitrofanova, Sukanya Panja
Life of this patent
Estimating the term…
Abstract
Methods for predicting the response of prostate cancer to androgen deprivation therapy (ADT) using a gene signature of five genes (CSPG5, FKBP6, FOSB, STMN1, and TTC27) is provided. Also provided are sets containing specific binding molecules for each of CSPG5, FKBP6, FOSB, STMN1, and TTC27 and kits containing such sets.
Claims19
A method of treating prostate cancer, comprising:
- (i) measuring
- mRNA expression of CSPG5, FKBP6, FOSB, STMN1, and TTC27 in a prostate cancer sample from the subject relative to a control for measuring mRNA expression, wherein the control for measuring mRNA expression is (1) a prostate cancer sample known to respond to androgen deprivation therapy (ADT) or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT;
- and/or
- DNA methylation within the TSS 200/1500, 5′ UTR, or 1st exon regions of CSPG5, FKBP6, FOSB, STMN1, and TTC27 in a prostate cancer sample from the subject relative to a control for measuring DNA methylation, wherein the control for measuring DNA methylation is (1) a prostate cancer sample known to respond to ADT or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT;
- (ii) determining that
- the subject with prostate cancer will respond to ADT when:
- TTC27, STMN1, and CSPG5 have decreased mRNA expression in the prostate cancer sample from the subject relative to the control for measuring mRNA expression and that FOSB and FKBP6 have increased mRNA expression in the prostate cancer sample from the subject relative to the control for measuring mRNA expression;
- and/or
- FKBP6 has decreased DNA methylation in the prostate cancer sample from the subject relative to the control for measuring DNA methylation and that FOSB, TTC27, STMN1, and CSPG5 have increased DNA methylation in the prostate cancer sample from the subject relative to the control for measuring DNA methylation;
- and
- (iii) administering ADT to the subject.
8 more elements
A method of treating prostate cancer in a subject, comprising:
- (i) measuring:
- decreased mRNA expression of TTC27, STMN1, and CSPG5 and increased mRNA expression of FOSB and FKBP6 in a prostate cancer sample from the subject relative to a control for measuring mRNA expression, wherein the control for measuring expression is (1) a prostate cancer sample known to respond to ADT or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT, and/or
- decreased DNA methylation within the TSS 200/1500, 5′ UTR, or 1st exon regions of FKBP6 and increased DNA methylation FOSB, TTC27, STMN1, and CSPG5 in a prostate cancer sample from the subject relative to a control for measuring DNA methylation, wherein the control for measuring DNA methylation is (1) a prostate cancer sample known to respond to ADT or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT;
- and
- (ii) administering ADT to the subject, thereby treating the prostate cancer, or
- (iii) measuring:
- increased mRNA expression of TTC27, STMN1, and CSPG5 and decreased mRNA expression of FOSB and FKBP6 in a prostate cancer sample from the subject relative to a control for measuring mRNA expression, wherein the control for measuring expression is (1) a prostate cancer sample known to respond to ADT or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT, and/or
- increased DNA methylation within the TSS 200/1500, 5′ UTR, or 1st exon regions of FKBP6 and decreased DNA methylation FOSB, TTC27, STMN1, and CSPG5 in a prostate cancer sample from the subject relative to a control for measuring DNA methylation, wherein the control for measuring DNA methylation is (1) a prostate cancer sample known to respond to ADT or (2) a reference value or range of reference values representing a prostate cancer sample known to respond to ADT;
- and
- (iv) administering radiation therapy, chemotherapy, or both, but not ADT, to the subject, thereby treating the prostate cancer.
7 more elements
Dependencies are inferred from the claim text.